Author: Vivian Xie 6th March 2026

In the pharmaceutical industry, compliance is an operational cornerstone for businesses looking to maintain their place in one of the world’s most heavily regulated sectors. In the United States, the Food and Drug Administration (FDA) is responsible for shaping the country’s regulatory landscape, ensuring the safety, efficacy, and quality of pharmaceutical products. 

However, following a string of recent FDA regulatory changes, the American pharma manufacturing sector has experienced significant disruptions to portfolio timelines. This has forced pharmaceutical manufacturing companies to make costly ongoing real-time adjustments to their labeling and pricing strategies in an effort to meet long-agreed launch dates. 

For CMOs in the pharma industry, these regulatory shifts have added another layer of complexity to an already demanding and increasingly disrupted supply chain. So how can these businesses rise to the challenges posted by changing FDA regulations, and what can be done to anticipate any uncertainty that arises in their wake? 

What Role Do FDA Regulations Play in Pharma Manufacturing? 

FDA regulations are designed to protect public health by ensuring that pharmaceutical products adhere to strict quality control standards around their own efficacy, and safety for the end user. These regulations govern the entire product lifecycle end-to-end, from clinical trials and manufacturing to labeling and post-market surveillance. 

However, the dynamic nature of these regulatory changes means that companies must constantly adapt to new requirements and guidelines. Recent examples of areas where organizations have had to take a more agile approach include accelerating approval pathways, updating labelling protocols, and post-market surveillance.  

With the increasing use and implementation of AI technologies, pharmaceutical regulatory agencies are under increasing scrutiny to implement a clear, trustworthy framework for the regulation of AI in manufacturing. In a roundtable discussion held on-site a CPHI Frankfurt, participants commented that “It’s not enough for one authority to approve something and for others to follow suit without due diligence. It’s important for regulatory bodies to take their time and ensure that decisions are made carefully and responsibly.” 

Furthermore, regulatory deadlines implemented by the US Environmental Protection Agency are also placing manufacturers under increasing pressure. Though reporting deadlines for PFAS-related data under the Toxic Substances Control Act have been extended, most manufacturers will have to submit detailed information on PFAS use, disposal, and health impacts by October 13, 2026. This data will further inform regulatory actions and policies. 

The only way for CMOs to stay comfortably ahead of these changes and continue delivering value to their clients is by preparing for any coming changes, and remaining compliant with existing regulations. 

Challenges in Navigating FDA Regulation Changes 

1. Disruption to Portfolio Timelines 

One of the most significant impacts of FDA regulatory changes is the chaos they can cause to established and agreed-upon timelines. As requirements around clinical trials, data submission, and approval processes are introduced, businesses will need to spend additional time ensuring their work complies with any new regulation. This can bring about delays to product launches, forcing companies to reevaluate their development strategies. For pharma manufacturing, these delays can have a ripple effect, impacting production schedules, resource allocation, and revenue forecasts. 

A recent report by McKinsey & Company explores the increased speed at which pharma companies are having to file portfolio timelines, often as a way of pre-empting these regulatory shifts. They note that ignoring evolving FDA requirements for clinical trials can bring about extended development timelines and increased costs for pharmaceutical companies (McKinsey, 2025). 

2. Uncertainty Around Product Launches 

Launching a finished product takes a great deal of forward planning, and the sign-off of multiple stakeholders across the supply chain. If pharmaceuticals contract manufacturing businesses are forced to adapt their processes to meet new requirements, this will have a detrimental impact on timelines for these projects. 

What’s more, as these long-established timelines change, then operational inefficiencies will be more likely to arise, increasing the risk of non-compliance. According to Deloitte’s 2025 Life Sciences Outlook, these changes can also impact different areas of pharma in different ways; as a specialism with an inherently more complex supply chain, medtech executives were more concerned with how these risks would impact their strategy (48% of respondents) than those in biopharma (30%) (Deloitte, 2025). 

3. Ongoing Adjustments to Labeling, Pricing, and Manufacturing Strategies 

FDA regulatory changes often necessitate ongoing adjustments to business strategies around labeling, pricing, and manufacturing. For example, after a number of states introduced new requirements for drug pricing transparency in 2025, companies were forced to reevaluate their pricing models, while changes in labeling guidelines have required significant updates to product packaging and marketing materials. 

PwC’s Health Research Institute notes that FDA pricing transparency initiatives are reshaping the pharmaceutical market, requiring companies to adopt more competitive and open pricing strategies to remain compliant (PwC, 2025). These adjustments can be particularly challenging for CMOs, who will have to balance the need for compliance with client demands. This often involves investing in new technologies, retraining staff, and implementing more robust quality control processes to ensure that products meet regulatory standards. 

Navigating Regulatory Uncertainty: Strategies for Success 

In the face of these challenges, pharmaceuticals manufacturing companies and CMOs must adopt proactive strategies to ensure that their businesses can stay compliant in the face of changing regulations. Here are three ways that organizations can keep operations running smoothly in the face of unpredictable regulatory changes: 

1. Investing in Regulatory Expertise 

Building a strong regulatory team is essential to ensure compliance and pre-empt any FDA regulatory changes. Companies should put money into hiring experienced regulatory professionals, and providing ongoing training to ensure that staff remain informed about the latest changes and how best to address them. 

2. Leveraging Technology 

Companies are also able streamline their regulatory processes and improve data management through the use of technology. Machine learning can be used to analyze regulatory guidelines and identify potential compliance risks, while the blockchain can increase transparency and traceability in supply chains. 

3. Collaborating with Industry Partners 

Working together is key for organisations looking for ways to successfully navigate regulatory uncertainty. By sharing information and experiences with CMOs, suppliers, and other industry partners, companies can pool resources to develop innovative solutions to address these ongoing challenges. 

4. Attending Industry Events 

Events like CPHI Americas provide a unique opportunity for industry professionals to connect, share knowledge, and explore solutions to regulatory challenges. By attending these events, companies can gain valuable insights into the latest trends and best practices in pharma manufacturing and pharmaceuticals contract manufacturing. 

The Path Forward: Building Resilience in Pharma Manufacturing 

As FDA regulations continue to evolve, success will be defined by the ability to adopt an agile approach to the ensuing uncertainty. For pharma manufacturing and pharmaceuticals contract manufacturing organizations, as well as CMOs and their clients, building this resilience will require a proactive approach that prioritizes collaboration, innovation, and adaptability. 

Investing in regulatory expertise, leveraging technology, and fostering collaboration are just a few of the strategies that can help companies overcome regulatory challenges and deliver value to their clients. The dynamic, challenging landscape of pharmaceutical regulations also offers immense opportunities for those who are willing to adapt and innovate.